Perampanel Serum Concentrations in Adults With Epilepsy

Therapeutic Drug Monitoring - Tập 38 Số 3 - Trang 358-364 - 2016
Philip N. Patsalos1,2,3, Marilia Gougoulaki1,3, Josemir W. Sander1,3
1NIHR University College London Hospitals Biomedical Research Centre, Department of Clinical & Experimental Epilepsy, UCL Institute of Neurology, Queen Square, London and Epilepsy Society, Chalfont Centre for Epilepsy, Chalfont St Peter, United Kingdom.
2Philip N. Patsalos, FRCPath, PhD, Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, United Kingdom (e-mail: [email protected]).
3The work undertaken by Professors P. N. Patsalos and J. W. Sander was performed at the UCLH/UCL Comprehensive Bio-Medical Research Centre, which received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. J. W. Sander receives research support from the Dr Marvin Weil Epilepsy Research Fund.

Tóm tắt

Từ khóa


Tài liệu tham khảo

Leddingham, 2013, Perampanel: what is its place in the management of epilepsy?, Neurol Ther, 2, 13, 10.1007/s40120-013-0012-3

Rogawski, 2011, Revisiting AMPA receptors as an antiepileptic drug target, Epilepsy Curr, 11, 56, 10.5698/1535-7511-11.2.56

Rogawski, 2013, Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist, Acta Neurol Scand Supp, 197, 19, 10.1111/ane.12100

Patsalos, 2015, The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist, Epilepsia, 56, 12, 10.1111/epi.12865

Vazquez, 2015, Perampanel efficacy and safety by gender: subanalysis of phase III randomized clinical studies in subjects with partial seizures, Epilepsia, 56, e90, 10.1111/epi.13019

Gidal, 2013, Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures, Epilepsia, 54, 1490, 10.1111/epi.12240

French, 2012, Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304, Neurology, 79, 589, 10.1212/WNL.0b013e3182635735

French, 2013, Evaluation of adjunctive perampanel in patients with refractory partial onset seizures: results of randomized global phase III study 305, Epilepsia, 54, 117, 10.1111/j.1528-1167.2012.03638.x

Krauss, 2012, Randomized phase III study306: adjunctive perampanel for refractory partial-onset seizures, Neurology, 78, 1408, 10.1212/WNL.0b013e318254473a

Johannessen Landmark, 2012, Methodologies used to identify and characterize interactions among antiepileptic drugs, Exp Rev Clin Pharmacol, 5, 281, 10.1586/ecp.12.10

Wu, 2014, Pharmacodynamic and pharmacokinetic interactions of perampanel and other antiepileptic drugs in a rat amygdala kindling model, Seizure, 23, 732, 10.1016/j.seizure.2014.06.001

Gidal, 2015, Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy, Neurology, 84, 1972, 10.1212/WNL.0000000000001558

Patsalos, 2002, The importance of drug interactions in epilepsy therapy, Epilepsia, 43, 365, 10.1046/j.1528-1157.2002.13001.x

Patsalos, 2008, Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies, Epilepsia, 49, 1239, 10.1111/j.1528-1167.2008.01561.x

Wen, 2001, In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9), Br J Clin Pharmacol, 52, 547, 10.1046/j.0306-5251.2001.01474.x

Gidal, 2003, Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy, Epilepsy Res, 57, 85, 10.1016/j.eplepsyres.2003.09.008

Löscher, 2007, The pharmacokinetics of antiepileptic drugs in rats: consequences for maintaining effective drug levels during prolonged drug administration in rat models of epilepsy, Epilepsia, 48, 1245, 10.1111/j.1528-1167.2007.01093.x

Markoula, 2014, Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose and concomitant antiepileptic drugs, Ther Drug Monit, 36, 494, 10.1097/FTD.0000000000000051

May, 1999, Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study, Ther Drug Monit, 21, 175, 10.1097/00007691-199904000-00007

Bockbrader, 2011, Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures, Epilepsia, 52, 248, 10.1111/j.1528-1167.2010.02933.x

Greenblatt, 1881, Clobazam kinetics in the elderly, Br J Clin Pharmacol, 12, 631, 10.1111/j.1365-2125.1981.tb01281.x

Ibarra, 2013, Sex related differences on valproic acid pharmacokinetics after oral single dose, J Pharmacokinet Pharmacodyn, 40, 479, 10.1007/s10928-013-9323-3

Marino, 2012, Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex, Clin Pharmacol Ther, 91, 483, 10.1038/clpt.2011.251

Smith, 1979, Factors influencing plasma concentrations of ethosuximide, Clin Pharmacokinet, 4, 38, 10.2165/00003088-197904010-00004

Perucca, 2008, Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy, Epilerpsia, 49, 1123, 10.1111/j.1528-1167.2008.01665.x

Thông tin
: []
Thông tin xuất bản

Therapeutic Drug Monitoring

Tập 38 Số 3

358-364

Thông tin tác giả